Ryeqo (relugolix;estradiol;norethisterone acetate)
- Region
- 🇪🇺 EU
- Active substance
- relugolix;estradiol;norethisterone acetate
- Company
- Gedeon Richter Plc.
- Status
- Authorised
- Therapeutic area
- Leiomyoma
- CHMP opinion
- Fri 16 Jul 2021
- EU approval
- Fri 16 Jul 2021
- Application
- EMEA/H/C/005267
- ATC
- H01CC54
- Official record
- www.ema.europa.eu
Indication
Ryeqo is indicated in adult women of reproductive age for: treatment of moderate to severe symptoms of uterine fibroids, symptomatic treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis.
Regulatory milestones
No milestones recorded in the last year.
Follow Ryeqo
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.